<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="to the blood–brain barrier (BBB) and the problems connected with" exact="systemic" post="administration, such as drug bioavailability and side-effects. For these"/>
 <result pre="penetration enhancers transmucosal delivery The blood–brain barrier (BBB) separates the" exact="central nervous system" post="(CNS) from the systemic circulation. The barrier characteristics of"/>
 <result pre="barrier (BBB) separates the central nervous system (CNS) from the" exact="systemic" post="circulation. The barrier characteristics of BBB depend on the"/>
 <result pre="the brain endothelial cells that constitute the walls of the" exact="blood vessels." post="There are many neurological diseases such as neurological infections,"/>
 <result pre="neurological diseases such as neurological infections, Parkinson’s disease, Alzheimer’s disease," exact="multiple sclerosis," post="age-related neurodegenerative diseases, and cerebral ischemia, that require a"/>
 <result pre="Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, age-related neurodegenerative diseases, and" exact="cerebral ischemia," post="that require a therapy in which the drug must"/>
 <result pre="must reach the brain. Furthermore, many of these diseases need" exact="chronic" post="therapies. Drug targeting to the brain represents a big"/>
 <result pre="for the nasal administration. The histopathological analysis of porcine nasal" exact="mucosa" post="showed that there was no infiltration of inflammatory cells"/>
 <result pre="the application of the nanoparticles on the structure of nasal" exact="mucosa" post="was determined by a histopathological study of untreated goat"/>
 <result pre="mucosa was determined by a histopathological study of untreated goat" exact="mucosa" post="and goat mucosa subjected to 24 h of the"/>
 <result pre="by a histopathological study of untreated goat mucosa and goat" exact="mucosa" post="subjected to 24 h of the permeation test. The"/>
 <result pre="by a sustained drug release. The histopathological examination of nasal" exact="mucosa" post="showed no toxicity or structural damages. The results obtained"/>
 <result pre="of drug loaded nanoparticles was carried out using swine nasal" exact="mucosa" post="compared to a drug suspension in phosphate buffer pH"/>
 <result pre="Cytotoxicity of the nanoparticles was tested on PC12 cells, as" exact="neuronal" post="model cells. These tests showed that nanoparticles are able"/>
 <result pre="nanoparticles are able to promote drug diffusion through the nasal" exact="mucosa" post="and do not show significant changes in terms of"/>
 <result pre="of antibodies for the treatment of neurological diseases [5]. The" exact="blood-brain barrier" post="(BBB) is a highly selective barrier and limits also"/>
 <result pre="use of antibodies for the therapy of diseases of the" exact="central nervous system" post="(CNS). The neonatal Fc receptor (FcRn) has a fundamental"/>
 <result pre="therapy of diseases of the central nervous system (CNS). The" exact="neonatal" post="Fc receptor (FcRn) has a fundamental role in the"/>
 <result pre="of the presence of FcRn in (ex vivo) porcine olfactory" exact="mucosa" post="and the evaluation of its role in nose-to-brain drug"/>
 <result pre="its role in nose-to-brain drug delivery. FcRn was found in" exact="epithelial" post="and basal cells of the olfactory epithelium, in glands,"/>
 <result pre="cells of the olfactory epithelium, in glands, cavernous bodies and" exact="blood vessels." post="Allogenic porcine IgGs were found time-dependently in the lamina"/>
 <result pre="IgGs were found time-dependently in the lamina propria and along" exact="axonal" post="bundles; small amounts of xenogenic human IgGs were detected."/>
 <result pre="authors were that Fc-mediated transport of IgG across the nasal" exact="epithelial" post="barrier may have significant potential for intranasal delivery, but"/>
 <result pre="testing in various environments were evaluated. The progression of Alzheimer’s" exact="disease" post="can be delayed by the anti-inflammatory and antiproliferative properties"/>
 <result pre="polymeric nanoparticles for the nose-to-brain delivery in the therapy of" exact="epilepsy" post="[7]. Epilepsy is one of the most common global"/>
 <result pre="for the nose-to-brain delivery in the therapy of epilepsy [7]." exact="Epilepsy" post="is one of the most common global neurological diseases."/>
 <result pre="of the most common global neurological diseases. Its therapy is" exact="chronic" post="and usually consists in oral or intravenous administrations of"/>
 <result pre="is reported an overview of nanotechnology approaches for crossing the" exact="blood-brain barrier" post="that involve different kinds of nanoparticles: polymeric nanoparticles, liposomes,"/>
 <result pre="architecture, physico-chemical characteristics and mucociliary clearance of the nasal olfactory" exact="mucosa" post="[10]. The authors review the &quot;state-of-the-art&quot; of the knowledge"/>
 <result pre="the knowledge of the characteristics of the nasal and olfactory" exact="mucosa" post="needed for a rational design of intranasal formulations. The"/>
 <result pre="potentially innovative approach in the treatment of CNS disorders and" exact="brain diseases." post="Conflicts of Interest The authors declare no conflict of"/>
 <result pre="declare no conflict of interest. References References 1.BonferoniM.C.FerraroL.PavanB.BeggiatoS.CavalieriE.GiunchediP.DalpiazA.Uptake in the" exact="central nervous system" post="of geraniol oil encapsulated in chitosan oleate following nasal"/>
 <result pre="delivery?Pharmaceutics20181010710.3390/pharmaceutics1003010730050027 6.RinaldiF.HaniehP.N.ChanL.K.N.AngeloniL.PasseriD.RossiM.WangJ.T.-W.ImbrianoA.CarafaM.MarianecciC.Chitosan glutamate-coated niosomes: A proposal for nose-to-brain deliveryPharmaceutics2018103810.3390/pharmaceutics1002003829565809 7.MusumeciT.BonaccorsoA.PuglisiG.Epilepsy" exact="disease" post="and nose-to-brain delivery of polymeric nanoparticles: An overviewPharmaceutics20191111810.3390/pharmaceutics1103011830871237 8.BonferoniM.C.RossiS.SandriG.FerrariF.GaviniE.RassuG.GiunchediP.Nanoemulsions"/>
</results>
